Series Hall, a medical technology company that leverages artificial intelligence (AI) to develop precision diagnostics and therapeutics, has raised $220 million in a Series B funding round. The funding was led by Tiger Global, with participation from existing investors such as Sequoia Capital, Casdin Capital, and OCV Partners. Series Hall will use the funding to expand its team and further develop its AI platform.
Founded in 2018, Series Hall uses machine learning and computational biology to identify biomarkers and targets for drug development. The company’s technology platform analyzes large amounts of genomic, imaging, and clinical data to develop diagnostics and therapies for cancer and other diseases. Series Hall’s platform also matches patients with the most effective treatments based on their individual genetic profiles.
The new funding will allow Series Hall to expand its AI platform and team of experts in AI, drug development, and clinical research. The company plans to focus on developing precision medicines for cancer and rare diseases, while exploring new therapeutic areas such as immunology and neurodegenerative diseases.
AI is transforming the healthcare industry by improving the accuracy and efficiency of medical diagnostics and therapies. According to a report by Grand View Research, the global market for AI in healthcare is expected to reach $31.3 billion by 2025, with a CAGR of 41.5%.
Series Hall’s focus on precision medicine reflects a growing trend in the healthcare industry. Precision medicine aims to provide targeted treatments for patients based on their individual genetic profiles, rather than a one-size-fits-all approach. This approach has the potential to improve treatment efficacy and reduce adverse effects.
The new funding round also reflects investor confidence in Series Hall’s business model and growth potential. Tiger Global’s Partner, John Curtius, commented on the investment, stating, “We are excited to support Series Hall as they continue to push the boundaries of precision medicine with their AI platform. The company’s focus on developing targeted therapies based on individual patient data is well-aligned with the future of healthcare, and we look forward to seeing their continued success in the industry.”
Series Hall’s CEO, Dr. Scott Dessain, commented, “We are grateful for the support of our investors as we continue to advance our AI platform and develop precision medicines that have the potential to transform the lives of patients. Our focus on leveraging AI and computational biology to accelerate drug discovery and development has positioned us at the forefront of the industry, and we look forward to continuing to drive innovation in precision medicine.”
In conclusion, Series Hall’s recent funding round is a testament to the growing trend of AI-powered precision medicine in the healthcare industry. The company’s focus on personalized medicine and efficiency will likely continue to be a key differentiator in the competitive healthcare industry. With a strong team of experts in AI, drug development, and clinical research, and a focus on leveraging technology to improve patient outcomes, Series Hall is well-positioned to continue driving innovation in precision medicine and transforming the lives of patients around the world.
